Exclusive: Boyi Group Closes Nearly RMB 100 Million Series B, Focusing on Localization of Core Protein Purification Materials

Recently, Changzhou Boyi Biological Group ("Boyi Group") announced that it has completed nearly RMB 100 million in Series B1 and B2 financing.

Among them, Series B1 was solely invested by BGI Songhe, and Series B2 was led by Jiangsu Qingke Industrial Investment Development Group Co., Ltd., with Jiangsu Changzhou High-End Functional Materials Industry Special Fund (Limited Partnership), Jiangsu Huai'an Digital and Intelligent Manufacturing Industry Special Fund (Limited Partnership) under Huaichuang Investment Group, and existing shareholders Jolmo Investment Management Co., Ltd. and BGI Songhe, as well as strategic investors, participating.

The Series B proceeds will mainly be used for R&D of new materials and intelligent protein purification systems, and to accelerate global commercialization and rollout.

Founded in January 2022, Boyi Group owns three major brands, Tiandirenhe, Boyi Bio and ACE, with business covering high-performance biological purification resins, high-efficiency life science research reagents, high-standard key raw materials and supporting technical services. With materials science as its underlying core technology, the company develops upstream and downstream tool products for life sciences around the protein research field, providing customers with overall solutions and striving to become a globally influential provider of intelligent protein research solutions.

Tiandirenhe was founded in 2013 by Boyi's founding team. Over the past decade and more, the company has started from zero and developed a number of core products including agarose resins, dextran, polymer resins, silica resins, magnetic beads and precast protein gels, forming a matrix of more than 300 purification products and achieving "100% in-house technology, 100% domestic supply chain and 100% self-produced core raw materials", meeting the full-scenario needs of biopharma from R&D to production.

In April this year, Boyi Group's new headquarters was officially opened, covering about 45 mu (roughly 3 hectares), with 10 fully automated biological purification resin production lines put into operation and a designed maximum single-batch capacity of 10,000 L, which will break through the industry's existing capacity ceiling. At the same time, Boyi's Huai'an precast gel production center also went into operation in April this year, doubling the company's precast gel capacity and production efficiency.

At present, Boyi Bio has embarked on a new journey of globalization and intelligence. On September 7, Boyi Bio signed a strategic cooperation agreement with BGI Yongsheng Intelligent, and the two sides will integrate advantageous resources in protein purification and automated intelligent equipment to explore a path for the intelligent upgrade of biomanufacturing.

Recently, based on more than 20 years of accumulated expertise in protein purification and drawing on a large body of literature and industry materials, the company launched Qianzhang, a full-process AI agent for protein purification scenarios that helps users start from necessary information and form an executable first-round small-scale trial plan. The company hopes to realize a full-industry-chain link of "intelligent equipment-functional materials-technical services", solving industry technical pain points and helping customers build efficient and stable protein R&D systems.